Highlights of This Issue 4303

SPECIAL FEATURES

4305 Food and Oral Antineoplastics: More Than Meets the Eye
Rajul K. Jain, Sajit S. Brar, and Lawrence J. Lesko
See article p. 4446

4308 Personalized Tamoxifen: A Step Closer but Miles To Go
Aditya Bardia and Vered Stearns
See article p. 4468

4311 Arsenic Trioxide and the Phosphoinositide 3-Kinase/Akt Pathway in Chronic Lymphocytic Leukemia
Dennis J. Goussetis and Leonidas C. Platanias
See article p. 4382

CCR New Strategies

4313 New Strategies in Pancreatic Cancer: Emerging Epidemiologic and Therapeutic Concepts
Donghui Li and James L. Abbruzzese

Molecular Pathways

4319 Overcoming Persistent Dependency on Androgen Signaling after Progression to Castration-Resistant Prostate Cancer
Masuo Yamaoka, Takahito Hara, and Masami Kusaka

4325 PI(3)King Apart PTEN's Role in Cancer
Siyuan Zhang and Dihua Yu

Report from the FDA

4331 U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab
Steven J. Lemery, Jenny Zhang, Mark D. Rothmann, Jun Yang, Justin Earp, Hong Zhao, Andrew McDougal, Anne Pilano, Raymond Chiang, Joseph E. Gootenberg, Patricia Keegan, and Richard Pazdur

4339 Transcriptional Profiling of Polycythemia Vera Identifies Gene Expression Patterns Both Dependent and Independent from the Action of JAK2V617F
Windy Berkofofsky-Fessler, Monica Buzzai, Marianne K-H. Kim, Steven Fruchtman, Vesna Najfeld, Dong-Joon Min, Fabricio F. Costa, Jared M. Bischof, Marcelo B. Soares, Melanie Jane McConnell, Weiija Zhang, Ross Levine, D. Gary Gilliland, Raffaele Calogero, and Jonathan D. Licht

4353 Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification
Sara De Brouwer, Katleen De Preter, Candy Kumps, Piotr Zabrocki, Michael Porcu, Ellen M. Westerhout, Arjan Lakeman, Jo Vandesompele, Jasmien Hoebecke, Tom Van Maerken, Anne De Paepe, Genevieve Laureys, Johannes H. Schulte, Alexander Schramm, Caroline Van Den Broecke, Joëlle Vermeulen, Nadine Van Roy, Klaus Beiske, Marleen Renard, Rosa Noguera, Olivier Delattre, Isabelle Janoueix-Lerosey, Per Kogner, Tommy Martinsson, Akira Nakagawara, Miki Ohira, Huib Caron, Angelika Eggert, Jan Cools, Rogier Versteeg, and Frank Speleman

4363 Upregulation of SOX9 in Lung Adenocarcinoma and Its Involvement in the Regulation of Cell Growth and Tumorigenicity
Shih Sheng Jiang, Wen-Tsen Fang, Ya-Hsue Hou, Shiu-Feng Huang, B. Linju Yen, Jinn-Liang Chang, Shih-Miao Li, Hui-Ping Liu, Ying-Lan Liu, Chih-Ting Huang, Yu-Wei Li, Te-Hsuan Iang, Shih-Hsuan Chan, Su Jing Yang, Chao A. Hsiung, Cheng-Wen Wu, Lu-Hai Wang, and I-Shou Chang
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4411</td>
<td>Notch1 Expression Predicts an Unfavorable Prognosis and Serves as a Therapeutic Target of Patients with Neuroblastoma</td>
<td>Hsiu-Hao Chang, Hsinyu Lee, Ming-Kuan Hu, Po-Nien Tsao, Hsueh-Fen Juan, Min-Chuan Huang, Yu-Yin Shih, Bo-Jeng Wang, Yung-Ming Jeng, Christina Ling Chang, Shiu-Feng Huang, Yeou-Guang Tsay, Fon-Jou Hsieh, Kai-Hsin Lin, Wen-Ming Hsu, and Yung-Feng Liao</td>
</tr>
<tr>
<td>4421</td>
<td>Prediction of Stage, Grade, and Survival in Bladder Cancer Using Genome-wide Expression Data: A Validation Study</td>
<td>Martin Lauss, Markus Ringnér, and Mattias Höglund</td>
</tr>
</tbody>
</table>

**CANCER THERAPY: PRECLINICAL**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4382</td>
<td>Induction of B-Chronic Lymphocytic Leukemia Cell Apoptosis by Arsenic Trioxide Involves Suppression of the Phosphoinositide 3-Kinase/Akt Survival Pathway via c-jun-NH₂ Terminal Kinase Activation and PTEN Upregulation</td>
<td>Javier Redondo-Muñoz, Elizabet Escobar-Díaz, Mercedes Hernández del Cerro, Atanasio Pandiella, María José Terol, José A. García-Marco, and Angeles García-Pardo</td>
</tr>
<tr>
<td>4434</td>
<td>Preclinical and Clinical Evidence that Deoxy-2-[¹⁸F]fluoro-d-glucose Positron Emission Tomography with Computed Tomography Is a Reliable Tool for the Detection of Early Molecular Responses to Erlotinib in Head and Neck Cancer</td>
<td>Sébastien Vergez, Jean-Pierre Delord, Fabienne Thomas, Philippe Rochaix, Olivier Caselles, Thomas Filleron, Séverine Brillouet, Pierre Canal, Frédéric Courbon, and Ben C. Allal</td>
</tr>
<tr>
<td>4392</td>
<td>Actinomycin D Decreases Mcl-1 Expression and Acts Synergistically with ABT-737 against Small Cell Lung Cancer Cell Lines</td>
<td>Haishan Xu and Geoffrey W. Krystal</td>
</tr>
</tbody>
</table>

**IMAGING, DIAGNOSIS, PROGNOSIS**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4452</td>
<td>Histopathologic and Immunohistochemical Characterization of Rash to Human Epidermal Growth Factor Receptor 1 (HER1) and HER1/2 Inhibitors in Cancer Patients</td>
<td>Beatrice Nardone, Kimberly Nicholson, Marissa Newman, Joan Guitart, Pedram Gerami, Nicholas Talarico, Ximing I. Yang, Alfred Rademaker, Dennis P. West, and Mario E. Lacouture</td>
</tr>
<tr>
<td>4410</td>
<td>Inconsistent Labeling of Food Effect for Oral Agents across Therapeutic Areas: Differences between Oncology and Non-Oncology Products</td>
<td>Soonmo Peter Kang and Mark J. Ratain</td>
</tr>
</tbody>
</table>

*See commentary p. 4311*
4461 The Effectiveness of Off-Protocol Adjuvant Chemotherapy for Patients with Urothelial Carcinoma of the Urinary Bladder

4478 Preclinical and Clinical Estimates of the Basal Apoptotic Rate of a Cancer Predict the Amount of Apoptosis Induced by Subsequent Proapoptotic Stimuli
Lian Zhang, Brian D. Kavanagh, Andrew M. Thorburn, and D. Ross Camidge

ABOUT THE COVER

This is an original study providing, from preclinical models to patients, a reliable proof of $^{18}$FDG-PET/CT efficiency as a surrogate marker for the early evaluation of EGFR-TKI (erlotinib) efficacy that may improve diagnostic accuracy of molecular effect (ERK1/2). The image represents a facial sagittal section of an $^{18}$FDG-PET/CT of a patient with an oropharyngeal head and neck squamous cell carcinoma. It reveals a tumor $^{18}$FDG uptake before patient exposure to erlotinib. For further details, please see the article by Vergez and colleagues on page 4434 of this issue.